文献速递妇科肿瘤

利用苏木精-伊红染色卵巢癌切片深度学习预测PARP抑制剂获益

Predicting benefit from PARP inhibitors using deep learning on H&E-stained ovarian cancer slides.
PubMed 文献 · Eur J Cancer · 2024-12-26

研究在AGO-TR1队列(n=208)训练基于苏木精-伊红染色全切片图像的深度学习模型预测同源重组缺陷(HRD),并在PAOLA-1队列(n=447)盲法测试其预测HRD及奥拉帕利获益的能力。模型外部验证AUROC仅57%,但模型定义的HRD阳性组中PARP抑制剂治疗患者无进展生存期(PFS)显著改善,HRD阴性组则无显著改善。作者认为基于深度学习的全切片图像分析可能生成PARP抑制剂获益预测器,但需更大队列和进一步方法学改进。

要点

  • 模型在AGO-TR1留出集HRD预测AUROC为72%,外部验证降至57%。
  • PAOLA-1中模型定义的HRD阳性组PARP抑制剂治疗PFS显著改善,HRD阴性组无显著改善。
  • 作者认为可能生成PARP抑制剂获益预测器,但需更大队列和方法学改进。

核心结论

  • 结果表明基于深度学习分析全切片图像可能生成PARP抑制剂获益预测器。
  • 但需更大队列和进一步方法学改进,以生成在独立患者队列中具有临床有用准确性的预测器。

研究设计与样本

  • 在AGO-TR1队列(n=208:108训练,100测试)的苏木精-伊红染色全切片图像上训练深度学习模型,以基于收缩质心的HRD为金标准。
  • 在PAOLA-1队列(n=447)中盲法测试模型预测Myriad分类器评估的HRD及奥拉帕利获益的能力。

主要发现

  • 模型在留出集HRD预测AUROC为72%,外部验证AUROC为57%。
  • Kaplan-Meier分析显示,PAOLA-1中模型定义的HRD阳性组接受PARP抑制剂治疗的患者PFS显著改善,HRD阴性组则无显著改善。
  • 模型定义的HRD阳性组中PARP抑制剂治疗患者的PFS改善 substantially longer,提示对PARP抑制剂获益有生物学意义的预测。

局限性

  • 外部验证HRD预测AUROC仅57%。
  • 需更大队列和进一步方法学改进,以生成在独立患者队列中具有临床有用准确性的预测器。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Ovarian cancer patients with a Homologous Recombination Deficiency (HRD) often benefit from polyadenosine diphosphate-ribose polymerase (PARP) inhibitor maintenance therapy after response to platinum-based chemotherapy. HR status is currently analyzed via complex molecular tests. Predicting benefit from PARP inhibitors directly on histological whole slide images (WSIs) could be a fast and cheap alternative. PATIENTS AND METHODS: We trained a Deep Learning (DL) model on H&E stained WSIs with "shrunken centroid" (SC) based HRD ground truth using the AGO-TR1 cohort (n = 208: 108 training, 100 test) and tested its ability to predict HRD as evaluated by the Myriad classifier and the benefit from olaparib in the PAOLA-1 cohort (n = 447) in a blinded manner. RESULTS: In contrast to the HRD prediction AUROC of 72 % on hold-out, our model only yielded an AUROC of 57 % external. Kaplan-Meier analysis showed that progression free survival (PFS) in the PARP inhibitor treated PAOLA-1 patients was significantly improved in the HRD positive group as defined by our model, but not in the HRD negative group. PFS improvement in PARP inhibitor-treated patients was substantially longer in our HRD positive group, hinting at a biologically meaningful prediction of benefit from PARP inhibitors. CONCLUSION: Together, our results indicate that it might be possible to generate a predictor of benefit from PARP inhibitors based on the DL-mediated analysis of WSIs. However, further studies with larger cohorts and further methodological improvements will be necessary to generate a predictor with clinically useful accuracy across independent patient cohorts.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Marmé F, Krieghoff-Henning EI, Kiehl L, et al. Predicting benefit from PARP inhibitors using deep learning on H&E-stained ovarian cancer slides. Eur J Cancer. 2024. PMID: 39742559. doi:10.1016/j.ejca.2024.115199

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。